Long Non-Coding RNA PVT1 Facilitates High Glucose-Induced Cardiomyocyte Death Through the miR-23a-3p/CASP10 Axis

Investigators observed that plasmacytoma variant translocation 1 (PVT1) and caspase‐10 were upregulated while miR‐23a‐3p was downregulated in high glucose‐induced cardiomyocytes. High glucose repressed cardiomyocyte activity and induced cardiomyocyte apoptosis, but this influence was antagonized by PVT1 knockdown or miR‐23a‐3p overexpression.
[Cell Biology International]
Xia, Y.-W., & Wang, S.-B. (n.d.). Long non-coding RNA PVT1 facilitates high glucose-induced cardiomyocyte death through the miR-23a-3p/CASP10 axis. Cell Biology International, n/a(n/a). https://doi.org/10.1002/cbin.11479 Cite
Abstract
Bookmark

No account yet? Register

0
Share

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Merck announced that the FDA has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

5-Aminolevulinic Acid-Mediated Photodynamic Therapy Can Target Aggressive Adult T Cell Leukemia/Lymphoma Resistant to Conventional Chemotherapy

With 16 primary blood samples from 13 patients, researchers demonstrated that photodynamic therapy efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute adult T cell leukemia/lymphoma.
[Scientific Reports]
Sando, Y., Matsuoka, K., Sumii, Y., Kondo, T., Ikegawa, S., Sugiura, H., Nakamura, M., Iwamoto, M., Meguri, Y., Asada, N., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., Utsunomiya, A., Oka, T., & Maeda, Y. (2020). 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. Scientific Reports, 10(1), 17237. https://doi.org/10.1038/s41598-020-74174-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

The authors describe the role of allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas, and summarize the published data and future perspectives in this area.
[Cancers]
Dumont, M., Peffault de Latour, R., Ram-Wolff, C., Bagot, M., & de Masson, A. (2020). Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers, 12(10), 2856. https://doi.org/10.3390/cancers12102856 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Between 2009 and 2015, scientists administered 46 CAR T-cell treatments to 43 patients. Patients had relapsed B-cell malignancies of the following types: diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma, low-grade B-cell lymphoma, or chronic lymphocytic leukemia.
[Immunotherapy]
Cappell, K. M., Sherry, R. M., Yang, J. C., Goff, S. L., Vanasse, D. A., McIntyre, L., Rosenberg, S. A., & Kochenderfer, J. N. (2020). Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, JCO.20.01467. https://doi.org/10.1200/JCO.20.01467 Cite
Abstract
Bookmark

No account yet? Register

0
Share

CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1+ B-cell lymphoma.
[Clinical Cancer Research]
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., Lu, Z., & Qian, W. (2020). CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-1457 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Tim-3 Promotes Tube Formation and Decreases Tight Junction Formation in Vascular Endothelial Cells

Tim-3 was overexpressed in vascular endothelial HMVECs and HUVECs and in vitro assays were used to determine that Tim-3 promoted cell proliferation, migration, invasion and tube formation through activating cyclin D1, Ras homolog gene family member A and vascular endothelial growth factor receptor 2.
[Bioscience Reports]
Cong, Y., Wang, X., Wang, S., Qiao, G., Li, Y., Cao, J., Jiang, W. G., & Cui, Y. (n.d.). Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells. Bioscience Reports. https://doi.org/10.1042/BSR20202130 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Transcription Factor C/EBPβ Orchestrates Dendritic Cell Maturation and Functionality Under Homeostatic and Malignant Conditions

Investigators found that IL-33 expression in a large subset of human glioma specimens and murine models correlated with increased tumor-associated macrophages/monocytes/microglia. In addition, nuclear and secreted functions of IL-33 regulated chemokines that collectively recruit and activated circulating and resident innate immune cells creating a pro-tumorigenic environment.
[Proceedings of the National Academy of Sciences of the United States of America]
Scholz, F., Grau, M., Menzel, L., Graband, A., Zapukhlyak, M., Leutz, A., Janz, M., Lenz, G., Rehm, A., & Höpken, U. E. (2020). The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2008883117 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Researchers studied the effect of blocking JAK pathway signaling on CAR T-cell proliferation, anti-tumor activity and cytokine levels in in vitro and in vivo models. They report that itacitinib, a potent, selective JAK1 inhibitor, was able to significantly and dose-dependently reduce levels of multiple cytokines implicated in CRS in several in vitro and in vivo models.
[Clinical Cancer Research]
Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy | Clinical Cancer Research. (n.d.). Retrieved October 5, 2020, from https://clincancerres.aacrjournals.org/content/early/2020/09/30/1078-0432.CCR-20-1739 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase I Dose Escalation and Expansion Trial

Researchers conduct a first-in-human trial of bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies.
[Nature Medicine]
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., Cunningham, A., Hamadani, M., Fenske, T. S., Dropulić, B., Orentas, R., & Hari, P. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine, 1–7. https://doi.org/10.1038/s41591-020-1081-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

BAFF-Driven NLRP3 Inflammasome Activation in B Cell

Scientists report BAFF engagement to BAFF receptor elicited both priming and activating signals for NLRP3 inflammasomes in primary B cells and B lymphoma cell lines.
[Cell Death & Disease]
Lim, K.-H., Chen, L.-C., Hsu, K., Chang, C.-C., Chang, C.-Y., Kao, C.-W., Chang, Y.-F., Chang, M.-C., & Chen, C. G. (2020). BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease, 11(9), 1–13. https://doi.org/10.1038/s41419-020-03035-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share